| |
All patients
N=431 |
Suppressed at study enrollment
N=388 |
Viremic at study enrollment
N=43 |
p value |
| Female |
325 (75%) |
291 (75%) |
34 (79%) |
0.56 |
| Age, median in years (range) |
38 (21, 64) |
38 (21, 64) |
36 (25, 60) |
0.35 |
| Born in South Africa |
414 (96%) |
373 (96%) |
41 (95%) |
0.80 |
| Education |
|
|
|
|
| Never been to school |
7 (2%) |
6 (2%) |
1 (2%) |
0.64 |
| Primary school |
42 (10%) |
39 (10%) |
3 (7%) |
|
| Secondary school |
357 (83%) |
319 (82%) |
38 (88%) |
|
| Tertiary school |
25 (6%) |
24 (6%) |
1 (2%) |
|
| In any form of a relationshipa |
|
|
|
|
| Yes |
250 (58%) |
227 (59%) |
23 (54%) |
|
| No |
181 (42%) |
161 (41%) |
20 (46%) |
0.53 |
| Months on ART, at study enrollment (range) |
45 (13, 152) |
45 (13, 152) |
45 (13, 55) |
0.86 |
| ART regimen |
|
|
|
|
| Efavirenz containingb |
393 (91%) |
357 (92%) |
36 (94%) |
|
| Stavudine containingc |
254 (59%) |
225 (58%) |
29 (67%) |
0.35 |
| VL prior to starting ART |
|
|
|
|
| Median copies/mL (range)d |
70 870
(1 078, >500 000) |
67 315
(2 102, >500 000) |
86 718
(1 078, >500 000) |
0.48 |
| CD4 prior to starting ART |
|
|
|
|
| Median cells/mm3 (range) |
93 (1, 444) |
95 (1, 760) |
107 (6, 314) |
0.34 |
| Mean |
96 |
104 |
109 |
0.74 |
| CD4 at study enrollment |
|
|
|
|
| Median cells/mm3(range) |
419 (16, 1 270) |
437 (119, 1 270) |
276 (16, 642) |
<0.01 |
| Prior exposure to ART |
|
|
|
|
| No |
335 (81%) |
308 (82%) |
27 (68%) |
|
| PMTCT only |
45 (11%) |
37 (10%) |
8 (20%) |
0.05f |
| Othere |
35 (8%) |
30 (8%) |
5 (13%) |
0.21 |
| Exposure to sdNVP or other ART vs. no exposuree |
80 (19%) |
67 (18%) |
13 (32%) |
0.03f |
| WHO stage prior to starting ART |
|
|
|
|
| I |
61 (21%) |
55 (20%) |
6 (25%) |
|
| II |
86 (29%) |
82 (31%) |
4 (17%) |
0.32f |
| III |
137 (47%) |
123 (46%) |
14 (58%) |
1.00f |
| IV |
9 (3%) |
9 (3%) |
0 (0%) |
--- |
ART, antiretroviral therapy; VL, virus load; WHO, world health organization, PMTCT, prevention mother-to-child-transmission by administrating a single dose nevirapine;
N, number
aYes: cohabitation, married, sexual relationship, No: Single/divorced/separated/widow
bThe other drug option was nevirapine
cThe other drug option was zidovudine
eVL done using Versant HIV-1 RNA 3.0 (Siemens Deerfield, IL, USA) bDNA technology
eExposure to other antiretroviral drugs prior to ART initiation
f2-sided Fisher exact test |
